ClinicalTrials.gg
CompletedNCT00778518Updated Oct 12, 2009

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

A Phase 2 interventional study of ARX201 and ARX201 in Growth Hormone Deficiency, sponsored by Ambrx, Inc.. Completed at 1 site in Hungary. Open to male participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2009-10-12.

Sponsored by Ambrx, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Dwarfism, Pituitary with a site in Hungary — none open to participants now, none under way, none of them phase 3. Dwarfism, Pituitary · Hungary.

Planned enrollment
9th of 11
36 · median 52
Started
2008
the only one that year
Phase 2
7 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
Ambrx, Inc.

Among the 12 studies in Dwarfism, Pituitary with a site in Hungary, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 2, and was the 2nd registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

None of the 12 studies in Dwarfism, Pituitary with a site in Hungary is open now. The open studies under Dwarfism, Pituitary, anywhere →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 30 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Dwarfism, Pituitary with a site in Hungary as a file.
02

Study summary

Study to find the optimal dose of Growth Hormone Replacement in young adult patients suffering from childhood onset growth hormone deficiency (GHD).

Read the detailed description

The primary objective of this study is to evaluate the safety, tolerability and pharmacodynamic response of three different ARX201 doses (PEG-ahGH) when administered repeatedly to young adult patients with childhood onset growth hormone deficiency (GHD).

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • growth hormone
  • growth hormone deficiency
  • GHD
  • PEG
  • pegylated
  • IGF-1
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-30 years old
  • GHD of childhood onset
  • completed growth
  • IGF-1 \<=2SDS
  • rhGH treatment naive
  • hGH levels below cut-off

Exclusion criteria

Exclusion Criteria:

  • History of or intracranial tumors
  • abnormality
  • ICH
  • hepatic dysfunction
  • renal impairment
  • major medical conditions
  • inadequate T4
  • positive for , , or
  • alcohol or drug abuse
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    1

    low dose

    Drug: ARX201

  • Active comparator
    2

    Medium dose

    Drug: ARX201

  • Active comparator
    3

    High Dose

    Drug: ARX201

Interventions

  • DrugARX201

    Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.

  • DrugARX201

    Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.

  • DrugARX201

    Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.

06

What researchers measure

Primary outcomes

  1. Temporal profiling of circulating IGF-1 levels.

    Time frame: 3 period

Secondary outcomes

  1. Body composition measurements at start of study and end of study

    Time frame: 6 months

07

Study locations

1 site
  • Accelsiors CRO and Consultancy Services
    Budapest, Hungary
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2008
First posted
Oct 23, 2008
Start
Jul 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
Oct 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00778518
Lead sponsor
Ambrx, Inc.
Collaborators
Merck Serono International SA
First posted
Oct 23, 2008
Start date
Jul 2008
Primary completion
Oct 2009
Completion
Oct 2009
Last update
Oct 12, 2009

Study contacts

Mihaly Juhasz, MD
study director · Accelsiors CRO & Consultancy Services

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion